Monocyte Depletion for High-Yield T Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for adoptive cell therapy, such as CAR-T and TCR-T therapies, face challenges in rapidly isolating, genetically modifying, and expanding lymphocytes while maintaining therapeutic efficacy and cell yield, particularly due to inhibitory effects from adherent cells like monocytes.
Innovation Solution
A method involving the depletion of adherent cells, specifically monocytes, from peripheral blood mononuclear cells using plastic adherence, followed by activation with anti-CD3 and anti-CD28 antibodies and transduction with viral vectors, to produce high yields of genetically modified CD8+ T cells within a short timeframe of 6 days.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If monocytes are not depleted from PBMCs, then the cell population maintains natural composition, but T cell purity and transduction efficiency are reduced
Solution Approach 1:
The patent applies monocyte depletion by removing adherent cells from the PBMC population through plastic adherence. This extraction of harmful monocytes from the cell mixture improves T cell purity and transduction efficiency without requiring complex additional devices, only simple adherence steps.
Solution Approach 2:
The patent performs monocyte depletion as a preliminary step before T cell activation and transduction. By removing monocytes in advance, the subsequent transduction process operates on a pre-purified cell population, improving overall efficiency and reducing the need for complex in-process controls.
2Productivity
If the manufacturing process is extended beyond 6 days, then cell expansion may be improved, but production time and costs increase
Solution Approach 1:
The patent optimizes critical parameters including monocyte depletion timing, activation conditions, and expansion culture conditions to achieve high cell yields within 6 days. By carefully controlling these parameters, the process achieves productivity goals without extending the time horizon.
Solution Approach 2:
The patent uses universal culture conditions and reagents that support both T cell activation and expansion in a streamlined manner. The same culture system performs multiple functions (activation, transduction, expansion) within the 6-day window, reducing the need for separate process steps that would extend duration.
3Reliability
If viral transduction is performed on activated T cells, then genetic modification efficiency is improved, but the risk of transduction-related adverse effects increases
Solution Approach 1:
The patent performs monocyte depletion before activation and transduction, creating a pre-purified T cell population. This preliminary action reduces the presence of monocytes that could be adversely affected by transduction or could interfere with T cell transduction, thereby improving safety while maintaining efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances the purity and yield of CD8+ T cells, improves transduction efficiency, and maintains functional viability, addressing the limitations of existing methods by increasing the number of usable T cells for therapy while reducing the process duration and costs.
Implementation Method 1
depleting the adherent cells, optionally monocytes
Data Source
AI summary
A method for producing an engineered T cell population includes obtaining a cell population containing a monocyte and a T cell, resting the obtained cell population on a surface, adhering the monocyte to the surface, retaining a non-adherent cell population, activating the non-adherent cell population, introducing a nucleic acid into the activated non-adherent cell population to obtain a transformed T cell, and expanding the transformed T cell to obtain the engineered T cell population.